Patient-derived cells have the potential to enhance drug screening tools and improve patient outcomes. Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse. A troubling rise in sun exposure and inconsistent sunscreen use may be linked to incidence of skin cancer in Canada. Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation. This provides rationale for the clinical evaluation of defactinib and avutometinib in the treatment of melanoma metastases. A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO. Dr. John Fruehauf details how novel therapies have improved the landscape of metastatic melanoma care. The main features of intestinal inflammation are reproduced as a biomarker for response to immune checkpoint inhibition. New research has uncovered a combination therapy that shows promising results in melanoma and breast cancer models. A recent study shows that macrophages can be used to predict whether or not a melanoma patient will respond to chemotherapy. A recent study found a connection between total serum calcium levels and developing melanoma. Dr. John Fruehauf provided an in-depth overview of treatments for metastatic melanoma. The primary outcomes of the study were melanoma-related deaths and nonmelanoma-related deaths. TPC2 and Rab7a interaction may be responsible for melanoma proliferation. Remote analysis of cancerous-looking skin growths yields the same level of accuracy as in-person analysis. Seventy-two percent of tumor specimens contained histologically defined LAs. The analysis included the CheckMate trials that involved ICI treatment-naive unresected/metastatic melanoma. Dr. John Fruehauf, Evolent, talks about a new standard of care in the treatment of stage III melanoma. The combo's use for conjunctival melanoma demonstrates the combinations high efficacy in treating complex disease. A novel method uses tumor-specific profiling to detect antibodies which are unique to early-stage melanoma.